Severe asthma — assessment & biologic therapy
T2-high phenotyping · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Severe asthma is uncontrolled or requiring high-dose ICS-LABA (+ a fourth controller) despite confirmed diagnosis, good adherence and technique. Biologics target type-2 (T2) inflammation and reduce exacerbations and oral steroid burden in eligible phenotypes.
Red flags
- Life-threatening exacerbations despite maximal therapy
- Rising eosinophils with rash/neuropathy/sinusitis suggesting EGPA
- OCS-dependence with cushingoid features and adrenal suppression
- New fever/weight loss suggesting infection or malignancy mimicking asthma
Assessment
Differential diagnosis
- Difficult-to-control (not truly severe) asthma — poor adherence/technique
- Inducible laryngeal obstruction / vocal cord dysfunction
- COPD or asthma-COPD overlap
- EGPA / eosinophilic lung disease
- ABPA
- Cardiac failure or chronic thromboembolic disease mimicking refractory breathlessness
Investigations
- Confirm diagnosis: spirometry with reversibility, FeNO, peak flow variability
- Blood eosinophil count (off/lowest OCS) and total IgE plus aeroallergen specific IgE / skin testing
- FeNO (T2 biomarker)
- Chest imaging (HRCT if atypical) and consider bronchoscopy if indicated
- Aspergillus IgE/IgG, ANCA, periostin where available
- Adherence check (prescription records, FeNO suppression test) and inhaler technique review
- Comorbidity screen: CRSwNP, GORD, OSA, obesity, anxiety
Management
- Confirm the diagnosis objectively and exclude mimics before labelling severe asthma
- Verify adherence (dispensing data, directly observed ICS/FeNO suppression) and correct inhaler technique
- Optimise treatable traits: nasal polyps, GORD, obesity, smoking, allergen/occupational exposures, psychosocial factors
- Ensure maximal inhaled therapy — high-dose ICS-LABA, add LAMA, consider trial of macrolide or LTRA per guideline
- Phenotype as T2-high vs T2-low using eosinophils, FeNO, IgE and allergen sensitisation
- Refer to a specialist severe-asthma service / MDT for biologic consideration
- Choose biologic by phenotype: anti-IgE (allergic), anti-IL5/IL5R (eosinophilic), anti-IL4R (broad T2), anti-TSLP (broad, biomarker-agnostic)
- Record baseline exacerbation rate, OCS dose, ACQ/ACT and FEV1 for response assessment
- Commence biologic and reassess response at ~4 months (exacerbations, symptoms, OCS, lung function)
- If responding, taper maintenance oral corticosteroids cautiously with adrenal-axis awareness
- If no response, reassess diagnosis/adherence and switch biologic class
- Arrange annual review, bone protection and steroid-sparing monitoring
Drugs & doses
Omalizumab 75-600 mg SC every 2-4 weeks (dose by weight and IgE)
Mepolizumab 100 mg SC every 4 weeks
Benralizumab 30 mg SC every 4 weeks x3 then every 8 weeks
Dupilumab 400 mg then 200 mg SC every 2 weeks (or 600/300 mg if OCS-dependent or with CRSwNP)
Tezepelumab 210 mg SC every 4 weeks
Prednisolone taper individualised while monitoring adrenal axis
Disposition
Specialist severe-asthma MDT clinic. Admit life-threatening exacerbations. Escalate OCS-dependent or EGPA-suspected cases to respiratory/immunology.
Complications & pitfalls
- Oral corticosteroid toxicity (osteoporosis, diabetes, cataract, adrenal suppression)
- Unmasking of EGPA on steroid/biologic taper
- Anaphylaxis to biologic (esp. omalizumab)
- Persistent airflow limitation / airway remodelling
Exam pearls
- A FeNO suppression test can distinguish non-adherence from true steroid-refractory disease
- Blood eosinophils fall on oral steroids — interpret biomarkers in that context
- Dupilumab can cause transient hypereosinophilia; monitor if baseline count is high
- Biologic response is judged at ~4 months, not weeks
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.